Page 2 - பெர்ன் பல்கலைக்கழகம் மருத்துவமனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SARS-CoV-2 mRNA vaccine efficacy reduced in patients with CD20-B-cell depleting treatment history Studies have shown that age and male sex are the key drivers for severe COVID-19, apart from other factors such as preexisting autoimmune conditions and malignancy. Scientists across the globe agree that the backbone of strategy that could lead to the end of this pandemic is mass vaccination. Although messenger RNA (mRNA) vaccines had high efficacy in randomized clinical trials, immunocompromised patients who might have inferior vaccination responses were not included in these trials. B-cell depleting therapies increase morbidity and mortality in COVID-19 patients. However, evidence-based vaccination strategies are lacking for this specific population. A better understanding of humoral and cell-mediated responses to mRNA vaccines in patients treated with anti-CD20 depleting agents could help develop individualized vaccination strategies. Recent data offered evidence that cell-mediated

Susha cheriyedathKateryna kon shutterstockBern university hospitalKateryna konபெர்ன் பல்கலைக்கழகம் மருத்துவமனை